Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention.
Urszula Adamiak-GieraAnna CzerkawskaSzymon OlędzkiMateusz KurzawskiKrzysztof SafranowMaria JastrzębskaBarbara Gawrońska-SzklarzPublished in: Pharmacological reports : PR (2020)
The CYP2C19*2 allele was associated with decreased platelet reactivity during clopidogrel therapy before and after PCI. Simultaneous determination of platelet aggregation and concentration of the inactive clopidogrel metabolite may be useful in clinical practice to find the cause of adverse effects or insufficient treatment effect in patients chronically treated with clopidogrel.
Keyphrases
- percutaneous coronary intervention
- acute coronary syndrome
- antiplatelet therapy
- st segment elevation myocardial infarction
- newly diagnosed
- acute myocardial infarction
- simultaneous determination
- ejection fraction
- coronary artery disease
- coronary artery bypass grafting
- stem cells
- heart failure
- gene expression
- bone marrow
- patient reported outcomes
- ms ms
- patient reported
- cell therapy
- coronary artery bypass
- copy number
- liquid chromatography
- high resolution mass spectrometry